Hadassah

Hadassah Physician Receives Hebrew University Award for Research on New Type 1 Diabetes Treatment

Thursday, Jun 14 2012

For her research on a new treatment for Type 1 diabetes, a Hadassah University Medical Center physician has received the Kaye Innovation Award from the Hebrew University. The treatment is now undergoing commercial development.

Dr. Chamutal Gur, a senior physician in Hadassah's Internal Medicine Department, as well as a Ph.D. student under the supervision of Prof. Ofer Mandelboim of the Institute for Medical Research Israel-Canada at the Hebrew University Faculty of Medicine, won the award for her research on the role of Natural Killer cells in autoimmune diseases. Her main project focuses on the function of the NKp46 killer receptor in Type 1 diabetes (T1D).

In people with T1D, autoreactive T cells attack the pancreatic beta cells, which produce natural insulin in the body. Natural Killer (NK) cells, which are part of our innate immune system, kill hazardous cells by using an array of cell receptors. One of the most potent is the NKp46 and Dr. Gur found that it specifically recognizes pancreatic beta cells, which leads to it destroying them.

Dr. Gur, in collaboration with other researchers at Hadassah and Ben-Gurion University, identified this phenomenon in both animal and human cell tests, demonstrating the importance of the NKp46 receptor in the development of diabetes. Concurrently, the research highlights the therapeutic potential of an anti-NKp46 monoclonal antibody (mAb) as a new treatment for T1D. Monoclonal cells are produced from a single ancestral cell by repeated cellular replication and, therefore, can be said to form a single "clone."

Based on the results, a patent was filed through the Hebrew University's Yissum Technology Transfer Company; Hadasit, the commercial arm of Hadassah; and BGN Technologies, the technology transfer company of Ben-Gurion University. The technology was licensed to BioLineRx to develop a blocking anti-NKp46 mAb for the treatment of T1D.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Jun 19 2018

American Journal of Ophthalmology Article Celebrates the Centennial of Hadassah Ophthalmology

The centennial anniversary of the Hadassah Medical Organization's Department of Ophthalmology is celebrated in the May issue of the American Journal of Ophthalmology, with an article by the immediate past director, Prof. Jacob Pe'er, and the current director, Prof. Itay Chowers.

READ MORE ›

Tuesday, Jun 12 2018

Hadassah Ophthalmology Department Research Highlighted by JAMA

Thanking the Hadassah Medical Organization’s researchers for their ”excellent submission” to JAMA Ophthalmology regarding a multi-center international study of the variable effectiveness of treatment for neovascular age-related macular degeneration (nAMD), the editors explained that their article was one of just a few from 12 JAMA on-line journals to be highlighted in The JAMA Network Reader this weekend.

READ MORE ›
alt_text

Monday, Jun 11 2018

Ruth Radiano: Passionate New Director of Nursing at Hadassah Hospital Mount Scopus

Translating her passion and professionalism into action, Ruth Radiano, the new Director of Nursing at Hadassah Hospital Mount Scopus, brings a background of 26 years of nursing at Hadassah.

READ MORE ›
alt_text

Thursday, Jun 7 2018

Former NYC Mayor Giuliani Calls Hadassah Hospital a Blessing

Former New York City Mayor Rudy Giuliani and his partner Dr. Maria Ryan, CEO of Cottage Hospital in Woodsville, New Hampshire visited Hadassah Medical Organization in Jerusalem today to get an update on Hadassah’s management of terror events.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More